Glycemic control and cardiovascular benefit: What do we know today?;Blutzucker-Senkung und kardiovaskuliärer Vorteil: Was wissen wir heute?

Deutsche Medizinische Wochenschrift

Volumn 135, Issue 7, 2010, Pages 301-307

  Hanefeld, M ^a   Schionauer M ^b   Forst, T ^c  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b Gemeinschaftspraxis Dr Schiönauer   (Germany)

^c IKFE GmbH   (Germany)

Author keywords

ACCORD; ADVANCE; Blood glucose control; DCCT; DIS; PROactive; RECORD; UKPDS; VADT

Indexed keywords

GLIMEPIRIDE PLUS ROSIGLITAZONE; GLITAZONE DERIVATIVE; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; PIOGLITAZONE; PLACEBO; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; AUTACOID; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

BODY MASS; GLYCEMIC CONTROL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; DIABETIC ANGIOPATHY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; MALE; METABOLISM; MORTALITY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; VASCULAR ENDOTHELIUM;

BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; LIPOPROTEINS; MALE; PPAR GAMMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; THIAZOLIDINEDIONES;

EID: 77049120741     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0029-1244853     Document Type: Review

References (43)

1. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein H C., Miller M E., Byington R P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 358 2545-2459
2. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 358 2560-2572
3. Al Majali K, Cooper M B., Staels B, Luc G, Taskinen M R., Betteridge D J. The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients. Diabetologia 2006 49 527-537
4. Aronoff S, Rosenblatt S, Braithwaite S, Egan J W., Mathisen A L., Schneider R L. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000 23 1605-1611
5. Berhanu P, Kipnes M S., Khan M A., et al. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diab Vasc Dis Res 2006 3 39-44
6. Campia U, Matuskey L A., Panza J A. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 2006 113 867-875
7. Ceriello A, Johns D, Widel M, Eckland D J., Gilmore K J., Tan M H. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care 2005 28 266-272 (Pubitemid 40170924)
8. Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005 48 1093-1104 (Pubitemid 40909644)
9. Daikeler R, Erdmann E, Forst T, et al. Wissenschaftlich Evidenz in der ärztlichen Praxis: 10 Thesen zur Wirksamkeit und Verträglichkeit einer Therapie mit Glitazonen. Diabetes, Stoffwechsel und Herz 2006 6 94-99
10. Deeg M A., Buse J B., Goldberg R B., et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007 30 2458-2464
11. Derosa G, Cicero A F., Dangelo A, et al. Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertens Res 2005 28 917-924
12. Derosa G, Cicero A F., Gaddi A, Ragonesi P D., Piccinni M N., Fogari E, Salvadeo S, Ciccarelli L, Fogari R. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract 2005 69 5-13
13. Dormandy J A., Charbonnel B, Eckland D J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005 366 1279-1289
14. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009 360 129-139
15. Erdmann E, Dormandy J A., Charbonnel B, Massi-Benedetti M, Moules I K., Skene A M. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007 49 1772-1780
16. Fernandez M, Triplitt C, Wajcberg E, et al. Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms. Diabetes Care 2008 31 121-127
17. Fällert S, Schneider F, Haak E, et al. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 2002 87 5503-5506
18. Goldberg R B., Kendall D M., Deeg M A at al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005 28 1547-1554
19. Hanefeld M, Brunetti P, Schernthaner G H., Matthews D R., Charbonnel B H., Study Group. QUARTET One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004 27 141-147
20. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch H J., Lindner J. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996 39 1577-1583
21. Hanefeld M, Schmechel H, Schwanebeck U, Lindner J. Predictors of coronary heart disease and death in NIDDM: the Diabetes Intervention Study experience. Diabetologia 1997 40 Suppl 2 S123-124
22. Hanefeld M, Temelkova-Kurktschiev T. The postprandial state and the risk of atherosclerosis. Diabet Med 1997 14 Suppl 3 S6-11
23. Holman R R., Paul S K., Bethel M A., Matthews D R., Neil H A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 359 1577-1589
24. Home P D., Pocock S J., Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009 373 2125-2135
25. Juurlink D N., Gomes T, Lipscombe L L., Austin P C., Hux J E., Mamdani M M. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 2009 339 b2942
26. Lawrence J M., Reid J, Taylor G J., Stirling C, Reckless J P. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care 2004 27 41-46
27. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino L J., DeFronzo R A. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002 87 2784-2791
28. Nathan D M., Cleary P A., Backlund J Y., et al. Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. N Engl J Med 2005 353 2643-2653
29. Nissen S E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007 356 2457-2471 (Pubitemid 46919772)
30. Pavo I, Jermendy G, Varkonyi T T., et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 2003 88 1637-1645
31. Pfätzner A, Marx N, Läbben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005 45 1925-1931
32. Pop-Busui R, Lombardero M, Lavis V, et al. Relation of severe coronary artery narrowing to insulin or thiazolidinedione use in patients with type 2 diabetes mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study). Am J Cardiol 2009 104 52-58
33. Ray K K., Seshasai S R., Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009 373 1765-1772
34. Roden M, Laakso M, Johns D, et al. Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus. Diabet Med 2005 22 1101-1106
35. Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003 26 2493-2499
36. Schernthaner G, Matthews D R., Charbonnel B, Hanefeld M, Brunetti P, Quartet Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004 89 6068-6076
37. Schneider C A., Ferrannini E, Defronzo R, Schernthaner G, Yates J, Erdmann E. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 2008 19 182-187
38. Szapary P O., Bloedon L T., Samaha F F., et al. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 2006 26 182-188
39. Tan M H., Glazer N B., Johns D, Widel M, Gilmore K J. Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes. Curr Med Res Opin 2004 20 723-728
40. Tan M H., Johns D, Strand J, et al. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes. Diabet Med 2004 21 859-866
41. Wilcox R, Bousser M G., Betteridge D J., Schernthaner G, Pirags V, Kupfer S, Dormandy J. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007 38 865-873
42. Winkler K, Konrad T, Fällert S, et al. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care 2003 26 2588-2594
43. Zietemann V, Storz P, Freytag A, Hagenmeyer E G., Gothe H. HTA Bericht zur Effektivität, zur Anwendungssicherheit und zur gesundheitsä konomischen Bewertung von Pioglitazon und Rosiglitazon bei der Behandlung des Typ 2 Diabetes mellitus. IGES Institut GmbH 2008 Berichts-Nr: HTAi006; http://gripsdb.dimdi.de/de/hta/hta-berichte/hta231-bericht-de.pdf